News

BUILT Biotechnologies Named Commonwealth BioAccelerator Anchor Company As Emerging Leader in DNA Manufacturing-as-Service Scales to Meet Exploding Demand

BUILT Biotechnologies, an emerging leader in DNA Manufacturing-as-a-Service, today announced its selection as an anchor company at the Commonwealth BioAccelerator, an initiative led by CvilleBioHub to strengthen Virginia’s biotechnology ecosystem. The relocation of BUILT’s headquarters to CvilleBioHub’s state-of-the-art facilities at North Fork Research Park positions the company to rapidly scale production in a new, next-generation laboratory to meet exploding demand and to grow its team by tapping Charlottesville’s talent pool.

Through its breakthrough Regenerative DNA Assembly™ process, BUILT is bridging the gap between DNA synthesis and ready-to-use DNA molecules for a growing roster of customers nationwide, from top-10 biopharma companies to university core facilities to small startups, enabling them to accelerate programs in cell and gene therapy, RNA therapeutics, and synthetic biology broadly.

The company routinely ships BUILT DNA™: sequence-perfect DNA constructs, including “unbuildable” long and complex molecules, in linear and plasmid formats. BUILT’s service provides biotech innovators with unparalleled capability, reliability, and speed, eliminating the need for in-house assembly and stepping up development timelines.

George McArthur, PhD, CEO of BUILT Biotechnologies, stated, “Our designation as an anchor company at the Commonwealth BioAccelerator validates BUILT’s rapid emergence as the partner of choice for the full range of life science operations seeking a more efficient and cost-effective way to access highest-quality, ready-built DNA. Our new North Fork lab will provide the capacity to scale and meet this pressing market need, as well as to recruit exceptional local talent and partner more closely with CvilleBioHub.”

With its expanded presence at North Fork, BUILT is also positioned to collaborate with the new Paul and Diane Manning Institute of Biotechnology at the University of Virginia, underscoring the company’s ability to serve innovators both globally and locally.

“BUILT exemplifies the kind of scale-ready company we’re proud to champion in Central Virginia,” said Nikki Hastings, PhD, Executive Director of CvilleBioHub. “As an anchor company of the Commonwealth BioAccelerator, BUILT strengthens our ecosystem by delivering the reliable, fast, and capable DNA manufacturing that growing therapeutics companies need to move from idea to impact.” The Commonwealth BioAccelerator, operated by CvilleBioHub and supported by public and private partners, provides companies with the resources and community to scale in Virginia’s biotech ecosystem.

Recent News

06/02/2026

TearSolutions Receives FDA Orphan Drug and Fast Track Designations for Lacripep® in Neurotrophic Keratitis and Initiates Phase 2 Clinical Trial with First Patients Dosed

TearSolutions, Inc. (“TearSolutions”), a clinical-stage biotechnology company developing novel ophthalmic therapeutics, today announced receiving Food and Drug Administration (FDA) Orphan Drug (ODD) and Fast Track Designations for Lacripep in Neurotrophic Keratitis (NK) and initiating a Phase 2 clinical trial with first patients dosed. The FDA’s ODD provides incentives, including tax credits for clinical testing and

06/02/2026

Contraline Announces $92.5 Million Series B Financing to Advance NES/T Male Contraceptive into Late-Stage Development

Contraline, Inc., a clinical-stage biopharmaceutical company developing novel male contraceptives, today announced the closing of a $92.5 million Series B financing co-led by BVF Partners L.P. and RA Capital Management, with participation from GV (Google Ventures), Lumira Ventures, Invus, and other new and existing investors. In conjunction with the closing of the Series B financing,

06/02/2026

GEN Names BioHealth Capital Region a Top 3 U.S. Biopharma Cluster for Fourth Year in a Row

The BioHealth Capital Region, spanning Maryland, Virginia, and Washington, D.C., has once again been named one of the nation’s Top 3 biopharma clusters by Genetic Engineering & Biotechnology News (GEN), marking the region’s fourth consecutive year in the Top 3. GEN’s 2026 “Top 10 U.S. Biopharma Clusters” ranking was authored by Alex Philippidis, Senior Business